Therapeutic exploratory study of the efficacy and safety of doripenem in patients with hospital-acquired pneumonia
|
Accession number;05A0663325
|
| Title;Therapeutic exploratory study of the efficacy and safety of doripenem in patients with hospital-acquired pneumonia |
| Author;
SAITO ATSUSHI
(Ryukyudai Daigakuin'igakukenkyuka Kansenbyotaiseigyogaku Bunshibyotaikansenshogakubun'ya)
WATANABE AKIRA
(Res. Inst. Tuberculosis and Cancer, Tohoku Univ.)
ITABASHI SHIGERU
(Shiogama Munic. Hosp.)
SAITO TAKEFUMI
(Ibarakihigashibyoin Kokyukinaika)
YAMAGUCHI KAZUHIRO
(Sch. of Med., Keio Univ.)
YOSHIMURA KUNIHIKO
(Fed. of Natl. Public Serv. and Affil. Personnel Mutual Aid Assoc., Toranomon Hosp.)
WATANUKI YUJI
(Kanagawa Prefectural Cardiovascular and Respiratory Diseases Center, JPN)
AOKI NOBUKI
(Shinrakuenbyoin Naika)
WADA KOICHI
(National Sanatorium Nishi-Niigata Chuou Hospital, JPN)
HAYAKAWA HIROSHI
(Tenryubyoin Naika)
NIKI YOSHITO
(Kawasaki Medical School, JPN)
HARA HIROKI
(Kurashikidaiichibyoin Naika)
KAWANISHI MASAYOSHI
(Kanedabyoin Naika)
KONO SHIGERU
(Nagasakidai Daigakuin'ishiyakugakusogokenkyuka Kansembunshibyotaigaku)
SHINZATO TAKASHI
(Ryukyudai Daigakuin'igakukenkyuka Kansenbyotaiseigyogaku Bunshibyotaikansenshogakubun'ya)
YAMAGUCHI KEIZO
(Toho Univ., School of Med.)
SHIMADA JINGORO
(St. Marianna Univ. School of Medicine, JPN)
|
Journal Title;Japanese Journal of Chemotherapy
|
Journal Code:F0608A
|
ISSN:1340-7007
|
|
VOL.53;NO.Supplement 1;PAGE.205-215(2005)
|
| Figure&Table&Reference;TBL.7, REF.17 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;We conducted a therapeutic exploratory study to evaluate the efficacy and safety of doripenem (DRPM), a new carbapenem antibiotic for injection, in 18 patients aged 44 to 95 years, with hospital-acquired pneumonia. Of these 18 were evaluated for DRPM efficacy and divided by dose as follows: 10 at 500 mg b.i.d., 3 at 500 mg t.i.d., 1 at 1,000 mg b.i.d., and 1 at a starting dose of 500 mg b.i.d. followed by 250 mg b.i.d. (downward titration based on improvement in symptoms and patient age). In all 1 of 18, DRPM was effective and clinical efficacy was evidenced as expected before the start of treatment. For safety, nonlaboratory adverse drug reactions were observed in only 1 case, pseudomembranous colitis. Laboratory adverse drug reactions were observed in 5, most in abnormal liver function tests. These results show that DRPM is useful for treating patients with hospital-acquired pneumonia. (author abst.) |
|
|
|
Related Articles;
|
|
